HIPRA
Since April 2020, Hipra has been developing a vaccine against SARS-CoV-2 with funding from the CDTI.2 Later, in November 2021, the vaccine went to phase 2 of human trials3, to finally start phase 3 in early 2022 with 3,000 volunteers in 20 hospitals, mainly from Spain but also from Italy and Portugal.